Results 121 to 130 of about 8,865 (194)

LHRH receptor targeting as mechanism of anti-tumor activity for cytotoxic conjugates of Disorazol Z with the LHRH receptor agonistic peptide D-Lys6-LHRH

, 2018
Aicher, Babette, Schuster, Tilmann, Blumenstein, Lars, Schubert, Antje, Gruendker, Carsten, Engel, Joerg B., Ortmann, Olaf, Mueller, Rolf, Guenther, Eckhard, Gerlach, Matthias, Teifel, Michael   +10 more
openaire   +1 more source

Luteinizing Hormone-Releasing Hormone (LHRH)-Conjugated Cancer Drug Delivery from Magnetite Nanoparticle-Modified Microporous Poly-Di-Methyl-Siloxane (PDMS) Systems for the Targeted Treatment of Triple Negative Breast Cancer Cells. [PDF]

J Funct Biomater
Eluu SC, Obayemi JD, Yiporo D, Salifu AA, Oko AO, Onwudiwe K, Aina T, Oparah JC, Ezeala CC, Etinosa PO, Osafo SA, Ugwu MC, Esimone CO, Soboyejo WO.   +13 more
europepmc   +1 more source

Oligometastatic Breast Cancer With Cutaneous Involvement and Paraneoplastic Hypercalcemia in a Young Woman. [PDF]

Cureus
Viana-Pereira M, Martins CH, Almeida M.
europepmc   +1 more source

Real-world treatment outcomes of abemaciclib in older patients with HR+, HER2- metastatic breast cancer in Japan. [PDF]

Future Oncol
Shimoi T, Tanizawa Y, Jin L, Sekine N, Nakayama T.   +4 more
europepmc   +1 more source

Understanding Peritoneal Fluid Estrogen and Progesterone Concentrations Permits Individualization of Medical Treatment of Endometriosis-Associated Pain with Lower Doses, Especially in Adolescents Not Requiring Contraception. [PDF]

J Clin Med
Koninckx PR, Ussia A, Adamyan L, Wattiez A, Vigano P.   +4 more
europepmc   +1 more source

Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges. [PDF]

Saudi Pharm J
Sakkal M, Abdelmoteleb RWA, Al Ali A, Jardan YAB, Löbenberg R, Sarfraz M.   +5 more
europepmc   +1 more source

Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. [PDF]

Oncologist
Beer TM, George DJ, Shore ND, Winters-Stone K, Wefel JS, Verholen F, Srinivasan S, Ortiz J, Morgans AK.   +8 more
europepmc   +1 more source

First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study. [PDF]

Medicina (Kaunas)
Yao S, Imoto S, Tsuchiya A, Isaka H, Seki H, Asaga S, Yokoi S, Koneri K, Maeda H, Goi T.   +9 more
europepmc   +1 more source

Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy. [PDF]

Breast
Shai A, Wildiers H, Venieri C, Pogoda K, Linderholm B, Lambertini M, Matos L, De Maio D'Esposito E, Hajjaji N, Matos E, González Cortijo L, Fotia G, Fortuna A, Sella T, Gouveia H, Rosset L, Constantinidou A, Angeli E, Cicin I, Tjan-Heijnen V, Ruyssers N, Demasure S, Abu Remilah A, Huygh G, Paluch-Shimon S, Chiappe E, Shirron N, Neven P, Artac M, Kilictas B, Baranseh J, Vicente-Rubio E, Atci M, Amato O, van Duijnhoven F.   +34 more
europepmc   +1 more source

Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer. [PDF]

Acta Pharm Sin B
Pérez-Herrero E, Fernández-Medarde A, Irache JM.   +2 more
europepmc   +1 more source